Barriers to clinical remission in severe asthma
Authors:
Open Access
- 24 April 2024
- journal article
- review article
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-8
Abstract
Severe asthma is associated with an increased risk for exacerbations, reduced lung function, fixed airflow obstruction, and substantial morbidity and mortality. The concept of remission in severe asthma as a new treatment goal has recently gained attention due to the growing use of monoclonal antibody therapies, which target specific pathologic pathways of inflammation. This review evaluates the current definitions of asthma remission and unveils some of the barriers for achieving this state in the severe asthma population. Although there is no unified definition, the concept of clinical remission in asthma should be based on a sustained period of symptom control, elimination of oral corticosteroid exposure and exacerbations, and stabilization of pulmonary function. The conjugation of these criteria seems a realistic treatment target in a minority of asthmatic patients. Some unmet needs in severe asthma may affect the achievement of clinical remission. Late intervention with targeted therapies in the severe asthma population may increase the risk of corticosteroid exposure and the development of irreversible structural airway changes. Moreover, airway infection is an important component in persistent exacerbations in patients on biologic therapies. Phenotyping exacerbations may be useful to guide therapy decisions and to avoid the liberal use of oral corticosteroids. Another challenge associated with the aim of clinical remission in severe asthma is the multifaceted interaction between the disease and its associated comorbidities. Behavioural factors should be evaluated in case of persistent symptoms despite optimised treatment, and assessing biomarkers and targeting treatable traits may allow for a more objective way of reaching remission. The concept of clinical remission will benefit from an international consensus to establish unifying criteria for its assessment, and it should be addressed in the future management guidelines.Keywords
This publication has 52 references indexed in Scilit:
- Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatmentAnnals of Allergy, Asthma & Immunology, 2023
- Executive summary: Japanese guidelines for adult asthma (JGL) 2021Allergology International, 2023
- Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAdvances in Therapy, 2022
- REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES StudyDrugs, 2021
- Dupilumab Treatment Leads to Clinical Asthma Remission in Patients With Uncontrolled Moderate-to-Severe Asthma With Type 2 InflammationJournal of Allergy and Clinical Immunology, 2021
- Characterization of Severe Asthma WorldwideChest, 2020
- An expert consensus framework for asthma remission as a treatment goalJournal of Allergy and Clinical Immunology, 2020
- Oral corticosteroid exposure and adverse effects in asthmatic patientsJournal of Allergy and Clinical Immunology, 2018
- Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature ReviewClinical Therapeutics, 2011
- Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic reviewArthritis Care & Research, 2009